PI3King the Lock: Targeting the PI3K/Akt/mTOR Pathway as a Novel Therapeutic Strategy in Neuroblastoma

@article{King2015PI3KingTL,
  title={PI3King the Lock: Targeting the PI3K/Akt/mTOR Pathway as a Novel Therapeutic Strategy in Neuroblastoma},
  author={D. King and D. Yeomanson and H. Bryant},
  journal={Journal of Pediatric Hematology/Oncology},
  year={2015},
  volume={37},
  pages={245–251}
}
Neuroblastoma is the most common extracranial cancer in childhood. High-risk neuroblastoma continues to have a poor prognosis and there is an urgent need to design biologically based therapies that specifically target the pathways responsible for malignant transformation and progression. One such pathway is the PI3K/Akt/mTOR pathway. In this article we outline the evidence for aberrant activation of the PI3K/Akt/mTOR pathway in neuroblastoma and discuss the possible mechanisms which mediate it… Expand
A review of the biological and clinical implications of RAS-MAPK pathway alterations in neuroblastoma
Targeting gallbladder cancer: a pathway based perspective
Molecular targeting therapies for neuroblastoma: Progress and challenges
Neuroblastoma treatment in the post-genomic era
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 53 REFERENCES
Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway
  • H. Burris
  • Medicine
  • Cancer Chemotherapy and Pharmacology
  • 2012
Paracrine Signaling Through MYCN Enhances Tumor-Vascular Interactions in Neuroblastoma
Analysis of PI3K/AKT/mTOR signalling pathway in high risk neuroblastic tumours.
A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma.
...
1
2
3
4
5
...